You are here

VERVE-102

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data

Clinical Trials Arena

Tue, 04/15/25 - 11:11 am

Verve Therapeutics

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Stock Titan

Mon, 04/14/25 - 09:44 am

Verve Therapeutics

clinical trials

cardiovascular disease

Verve gets FDA green light to expand base editing trial into US

BioPharma Dive

Tue, 03/25/25 - 10:22 am

Verve Therapeutics

clinical trials